Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13

PUMA BIOTECHNOLOGY, INC.

Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.
AstraZeneca's motion to dismiss Puma as plaintiff granted on standing grounds; Puma remains counterclaim-defendant.
Puma retains contractual rights under Pfizer license to seek monetary damages in the case.
Jury trial scheduled for May 13, 2024 in Delaware federal court.
Suit alleges Tagrisso infringes patents licensed exclusively to Puma; Wyeth continues as co-plaintiff.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.